Adwaita Gore

Medical Oncologist, Hemato Oncologist, Executive Editor Indian Journal of Cancer, Cyclist, Amateur Photographer

[MV Chandrakanth @ChandrakanthMv]

FDG vs FAPI PET 👀
• Cell activity vs Tumor ecosystem
• Brain mets – who wins?
• Peritoneal disease – cleaner imaging?
• Faster workflow, no fasting?
Are we approaching selective shifts in oncology imaging?
#Oncology #NuclearMedicine #PETCT #MVOnco

[Oncology Brothers @OncBrothers]

This is a slide by @drsarahsam from @DanaFarber that I have referred to heavily in my own clinical practice with my patients whenever we are discussing adjuvant CDK 4/6i

[Dr Amol Akhade @SuyogCancer]

Great talk by @VanitaNoronha at #ASCO25 . Nice slide for take home message and limitations of 3 studies and presented post EGFR progression.
Most important is LMIC perspective. 👍 @TataMemorial @OncoAlert @Alfdoc2

[soria @jsoriamd]

Carcinoma of Unknown Primary: Cancer without a past
🧬 Early dissemination
🛡️Immune editing of the primary
🧪CK20+, CDX2+, SATB2+ → treat colon-like
🧭Let biology, not anatomy, guide therapy
Not a diagnostic failure — a metastatic strategy.
https://t.co/fTKLByy1RF
#ASCO25 #CUP #CancerBiology

[Dr Amol Akhade @SuyogCancer]

📢 ASCENT-03 delivers for Trodelvy in 1L mTNBC!
❤ Trodelvy (sacituzumab govitecan) shows a statistically significant & clinically meaningful PFS benefit vs chemo
❌ In a tough group: PD-L1–negative or IO-ineligible mTNBC
🧬 First ADC to potentially become 1L backbone for all-comers
⚖️ Second positive Ph3 trial in 1L mTNBC for Trodelvy
🧪 No OS data yet, but strong case for chemo-free frontline option in non-IO patients

#TNBC #ADC #OncoX #Gilead #BreastCancer @OncoAlert
@stolaney1 @OncBrothers

[Yakup Ergün @dr_yakupergun]

#ASCO25

INAVO120: Inavo + palbo + fulvestrant in 1L PIK3CA-mutant HR+/HER2– aBC

OS ➡️ 34.0 vs 27.0 mo✅️
PFS ➡️ 17.2 vs 7.3 mo
TTC ➡️ 35.6 vs 12.6 mo

Hyperglycemia (any) ➡️ 63.4% vs 13.5%

Clear OS benefit & ~2y chemo delay—an important advance in endocrine-resistant HR+ aBC

[Jeff Sharman @jeff_sharman]

BTK inhibitors have transformed the lives of many patients with Chronic Lymphocytic Leukemia and other lymphomas. These drugs "exploded" onto the scene in 2013-2014 and have fundamentally changed the way we treat the disease. What many people don't know is how it all happened..

[Adwaita Gore @AdwaitaGore]

Revolutionizing neuro-oncology! Targeted therapies are bringing precise treatments for CNS tumors. New advances in IDH-mutant gliomas are showing great promise, despite challenges like the blood-brain barrier. #NeuroOncology #BrainTumorResearch

https://t.co/BAGIGdOkL3

[Adwaita Gore @AdwaitaGore]

Cancer is rising in India with 1.4M new cases yearly. Early screening for breast, cervical, oral cancers saves lives. Join NPCDCS, NGOs & campaigns for accessible tests. Spread awareness! #CancerScreeningIndia #EarlyDetectionSavesLives #FightCancer https://t.co/Pq58GjengI

[anand mahindra @anandmahindra]

Our prayers are with our forces…

One nation…Together we Stand

[Anan Bseiso @AnanBseiso]

Crazy how fast pathologists have to stay on top of updates! Just this week—HER2 expression guidelines were updated and presented at #USCAP2025. Never a dull moment! #Pathology

[Yakup Ergün @dr_yakupergun]

Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial

💥In this trial involving clinically node-negative, T1 (90%) or T2 breast cancer patients, omitting surgical axillary staging was noninferior to SLNB after 6 years of follow-up.
https://t.co/ya9WYId8no

[Dr Amol Akhade @SuyogCancer]

How to select older patients with EBC for chemotherapy. Useful tools for clinical practice. @SG_BCC

[Adwaita Gore @AdwaitaGore]

Universal testing for BRCA 1 BRCa2 and PALB2 all BC cases. Knowing the mutation translates to better outcomes.

[Adwaita Gore @AdwaitaGore]

ctDNA is emerging as a promising surrogate marker in breast cancer research. It offers a non-invasive way to monitor disease progression, treatment response, and recurrence risk. @SG_BCC

[Adwaita Gore @AdwaitaGore]

"Circulating Tumor Cells (CTCs) are a game-changer in breast cancer detection! These cells, shed by tumors into the bloodstream, offer a non-invasive 'liquid biopsy' to monitor cancer progression and treatment response. currently use in clinical trial setting only.

[Dr Amol Akhade @SuyogCancer]

Time taken by various drugs to move from MBC to EBC .
Pembrolizumab took it 3 years .
How much time trastuzumab deruxtecan will take ? Slide by @curijoey #SGBCC2025 @OncoAlert @OncBrothers @dr_yakupergun @stolaney1 @ErikaHamilton9

[Adwaita Gore @AdwaitaGore]

Pleasure listening to Dr. Antonio Giuliano, Plenary @ SGBCC2025 - Z011 trial evaluated the necessity of ALND in T1-2 invasive BC and 1-2 positive SLN undergoing lumpectomy + WBRT, found no significant difference in 10-year OS, DFS, LRRFS. Real practice change for Breast Surgery !

[Adwaita Gore @AdwaitaGore]

@SuyogCancer @dr_yakupergun Only imaging as a parameter - generally we do the biopsy. If we take into consideration other parameters like HBV or HCV positive status, High AFP, and the imaging then we don’t do the biopsy in most of such cases. Comfortable starting therapy for these patients without biopsy.

[Adwaita Gore @AdwaitaGore]

@SuyogCancer @SG_BCC Will be there in person. Have a poster presentation there.